Comparative Pharmacology
Head-to-head clinical analysis: RAUVAL versus TEKTURNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUVAL versus TEKTURNA.
RAUVAL vs TEKTURNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life is approximately 24 hours (range 20–40 hours), supporting once-daily dosing.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Primarily renal (88% as unchanged drug and metabolites, 33% as unchanged aliskiren); biliary/fecal elimination accounts for approximately 12%.
Category C
Category C
Antihypertensive
Antihypertensive